PPIDT00066
Drug Information
| Name | Ibritumomab tiuxetan |
|---|---|
| Sequence | QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR |
| DrugBank_ID | DB00078 |
| Type | biotech |
| Indication | For treatment of non-Hodgkin's lymphoma |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous; Parenteral |
1.6 MG/ML
|
| Injection; kit | Intravenous |
1.6 mg/1mL
|
| Kit | Intravenous |
1.6 mg/1mL
|
| Kit | Intravenous |
1.6 mg/ml
|
| Solution | Intravenous |
320000 mg
|